Edesa Biotech, Inc.
332 E. Scott St.
Port Hueneme
California
93401
United States
Tel: 805.488.2800
Website: http://edesabiotech.com/
261 articles about Edesa Biotech, Inc.
-
Edesa Biotech to Present at H.C. Wainwright & Co. 6th Annual Israel Conference
11/6/2020
Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company, announced today that Dr. Par Nijhawan, Chief Executive Officer, is scheduled to present at the H.C. Wainwright 6th Annual Israel Conference on November 12, 2020 at 12:30 pm ET.
-
Edesa Biotech Achieves Enrollment Milestone in Dermatitis Study
11/3/2020
Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company, today announced that it has completed enrollment of more than 50% of the patients planned for the first cohort of a Phase 2b clinical study
-
Edesa Biotech Receives Approval to Initiate COVID-19 Study in the U.S.
10/19/2020
Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company, has received clearance from the U.S. Food and Drug Administration (FDA) to begin the Phase 2 portion of its Phase 2/3 clinical study of its investigational drug, EB05,
-
Pardeep Nijhawan Acquires Beneficial Ownership of Additional Securities of Edesa Biotech, Inc.
9/18/2020
Dr. Pardeep Nijhawan announces that his beneficial ownership of common shares in the capital of Edesa Biotech, Inc. has increased by more than 2% of the issued and outstanding Common Shares from the amount reported in the early warning report Dr. Nijhawan filed dated May 11, 2020.
-
Edesa Biotech Reports Fiscal 3rd Quarter 2020 Results
8/12/2020
Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company, today reported financial results for the three and nine months ended June 30, 2020 and provided an update on its business.
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for July 31, 2020.
-
Edesa Biotech Files IND Application for Phase 2/3 COVID-19 Study
7/30/2020
Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company, has filed an investigational new drug (IND) application with the U.S. Food and Drug Administration (FDA) for the initiation of a Phase 2/Phase 3 clinical study of its investigational drug, EB05, for the treatment of hospitalized COVID-19 patients.
-
Edesa Biotech Receives Regulatory Approval to Initiate COVID-19 Study
6/15/2020
Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company, has received expedited approval from Health Canada to begin a Phase 2/3 clinical study of its investigational drug, EB05, which the company is developing as a potential treatment for moderate to severe COVID-19 patients.
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 15, 2020.
-
Edesa Biotech Receives Approval to Proceed with U.S. Clinical Study
6/20/2019
Edesa Biotech, Inc. reported that the U.S. Food and Drug Administration has notified the company that it may proceed with its clinical investigation of EB01, a novel sPLA2 inhibitor, which Edesa is developing as a potential treatment for chronic allergic contact dermatitis.
-
Pardeep Nijhawan Acquires Common Shares of Stellar Biotechnologies, Inc.
6/10/2019
Following the completion of the Exchange, the Issuer changed its name to "Edesa Biotech, Inc." and Dr. Nijhawan was appointed as the Chief Executive Officer and Secretary of the Issuer.
-
Edesa Biotech and Stellar Biotechnologies Complete Business Combination
6/7/2019
Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, today reported that the previously announced business combination with Stellar Biotechnologies, Inc. (Nasdaq: SBOT) ("Stellar"), which was completed pursuant to a share exchange agreement, has closed.
-
Stellar Biotechnologies Reports Second Quarter Financial Results
5/8/2019
Stellar Biotechnologies, Inc. reported financial results for the three and six months ended March 31, 2019 and provided an update on its business.
-
Stellar Biotechnologies and Edesa Biotech Sign Share Exchange Agreement
3/8/2019
Stellar Biotechnologies, Inc. has executed a share exchange agreement with privately-held Edesa Biotech Inc., a Canadian company, and Edesa's shareholders to create a company focused on the development of innovative therapeutics for dermatological and gastrointestinal indications with clear unmet medical needs.
-
Stellar Biotechnologies Reports First Quarter Financial Results
2/5/2019
Stellar Biotechnologies, Inc. (Nasdaq: SBOT), a leading manufacturer of a key protein utilized in multiple immunotherapy and immuno-oncology development pipelines, today reported financial results for the three months ended December 31, 2018 and provided an update on its business.
-
Stellar Biotechnologies Reports Fiscal Year 2018 Financial Results
11/30/2018
LOS ANGELES, /PRNewswire/ -- Stellar Biotechnologies, Inc. (Nasdaq: SBOT), a leading manufacturer of a key protein utilized in multiple immunotherapy and immuno-oncology development pipelines, today reported financial results for the fiscal year ended September 30, 2018 and provided an update on its business
-
Stellar Biotechnologies to Present at BlueTech Summit 2018
10/31/2018
Stellar Biotechnologies, Inc. announced today that Stellar President and CEO Frank R. Oakes will present at the 10th Annual BlueTech Summit to be held November 5-9, 2018 in San Diego, California.
-
Stellar Biotechnologies to Supply KLH to National Institutes of Health
9/5/2018
Initiated product manufacturing for the NIH's National Cancer Institute, which plans to use a vialed formulation of Stellar KLH in dendritic cell-based cancer therapies.
-
Stellar Biotechnologies to Present at H. C. Wainwright Global Investment Conference
8/28/2018
20th Annual Global Investment Conference to be held September 4-6, 2018 in New York City.
-
Stellar Biotechnologies Reports 2018 Third Quarter Financial Results
8/8/2018
Stellar Biotechnologies, Inc. reported financial results for the three and nine months ended June 30, 2018 and provided an update on its business.